An Observational Postauthorization Safety Study To Describe The Safety Of Ustekinumab and Other Biologic Treatments in a Cohort of Patients With Ulcerative Colitis or Crohn’s Disease Using Compulsory Swedish Nationwide Healthcare Registers and the Independent Swedish National Quality Register for Inflammatory Bowel Disease (SWIBREG) (Stelara UC/CD PASS (SWIBREG))

ENCePP Code of conduct

No

Data sources

• Data source(s), other:
  Swedish Cancer Register Sweden, Total Population Register Sweden, National Patient Register (NPR) Sweden, Infectious Disease Register (IDR) Sweden, Prescribed Drug Register (PDR) Sweden
• Data sources (types):
  Disease registry

  Other
• Data sources (types), other:
  Case-control surveillance database

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No